This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Alzheimer Disease
and you are
between 18 and 55
years old
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This is a Phase 1, randomized, double-blind, placebo-controlled, 6-period crossover study to evaluate the effects of BPN14770 10 mg and 50 mg in reversing scopolamine-induced cognitive impairment in healthy volunteers. A positive control, donepezil 10 mg, will be included, and additivity of BPN14770 50 mg to donepezil 10 mg in reversing scopolamine effects will also be evaluated.

Provided treatments

  • Drug: BPN14770
  • Drug: BPN14770 placebo
  • Drug: Donepezil
  • Drug: Donepezil placebo
  • Drug: Scopolamine 0.6 MG/ML
  • Drug: Scopolamine placebo
Tris trial is registered with FDA with number: NCT03030105. The sponsor of the trial is Tetra Discovery Partners and it is looking for 38 volunteers for the current phase.
Official trial title:
A Randomized, Double-blind, Placebo-controlled, Single-dose, 6-Period Crossover Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers